Revolution Medicines Begins Treating Patients in Phase 3 Trial of Zoldonrasib Combination for Lung Cancer

• Revolution Medicines began treating patients in Phase 3 RASolve 308 testing zoldonrasib as first-line therapy for metastatic RAS G12D non-squamous NSCLC.
• The global, randomized trial compares zoldonrasib with placebo, each combined with pembrolizumab and platinum-based chemotherapy.
• The primary goal is to assess whether the regimen delays disease progression; secondary measures include survival and safety.
• Initial clinical data already showed encouraging preliminary antitumor activity with a favorable safety profile for the combination in previously untreated patients.
• The targeted population accounts for approximately 4% of NSCLC cases, with no approved targeted treatment options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200800PRIMZONEFULLFEED9849085) on October 20, 2026, and is solely responsible for the information contained therein.